Novo Nordisk A/S (NVO) : The money flow analysis of Novo Nordisk A/S (NVO) indicates a $15.73 million of outflow was on downticks, whereas, the investors on Wednesday gobbled up stocks worth $20.12 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.28 and so was the total money flow at $4.4 million. The bulls lapped up $3.6 million worth of block trades on upticks. The money flow was $3.6 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Novo Nordisk A/S (NVO), pushing it down by -0.25% for the day. The stock slid $0.11 and traded at $43.74 during the day. Nonetheless, the stock is -2.54% over the previous weeks close.
Novo Nordisk A/S has lost 5% in the last five trading days and dropped 7.04% in the last 4 weeks. Novo Nordisk A/S has dropped 16.7% during the last 3-month period . Year-to-Date the stock performance stands at -22.63%.
Novo Nordisk A/S (NVO) : 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Novo Nordisk A/S (NVO). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 3 Wall Street Analysts endorse the stock as a Hold with a rating of 3.
Novo Nordisk A/S (NYSE:NVO): stock was range-bound between the intraday low of $43.44 and the intraday high of $43.97 after having opened at $43.92 on Wednesdays session. The stock finally closed in the red at $43.92, a loss of -0.25%. The stock remained in the red for the whole trading day. The total traded volume was 2,922,264 shares. The stock failed to cross $43.97 in Wednesdays trading. The stocks closing price on Thursday was $43.85.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.